Liso-cel transgene persistence∗ (A) (cellular kinetic set) and incidence of B-cell aplasia† (B) (liso-cel–treated efficacy analysis set). ∗Number of patients with persistence of liso-cel in the blood/number of patients with an available sample at the specific time point. Persistence is defined as a transgene count greater than, or equal to, the lower limit of detection. Data obtained after the initiation of retreatment with liso-cel or after start of a new anticancer therapy are not included in the determination of persistence. †Number of patients with B-cell aplasia/number of patients with an available sample at the specific time point. B-cell aplasia is defined as <3% CD19⁺ B cells in peripheral blood lymphocytes; B-cell measurements taken after the initiation of retreatment or after another anticancer treatment are excluded. tx, treatment.